A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

Published:2014-02 Issue:2 Volume:16 Page:63-71
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Jani Rajendrakumar H.¹,Pai Vikas²,Jha Pramod³,Jariwala Gunjan¹,Mukhopadhyay Satinath⁴,Bhansali Anil⁵,Joshi Shashank⁶

Affiliation:

1. Clinical R & D, Cadila Healthcare Ltd., Ahmedabad, India.

2. Pai Clinic & Diagnostic Centre, Pune, Maharashtra, India.

3. Government Medical College & Sir T. Civil Hospital, Bhavnagar, Gujarat, India.

4. Institute of Postgraduate Medical Education & Research, Kolkata, India.

5. Postgraduate Institute of Medical Education & Research, Chandigarh, India.

6. Joshi Clinic, Mumbai, India.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2013.0253

Reference16 articles.

1. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

2. Management of Diabetes Mellitus in Patients With Cardiovascular Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

3. Standards of Medical Care in Diabetes—2013

4. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)

5. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes;Atherosclerosis;2024-07

2. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future;Biomedicines;2024-06-21

3. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD;Metabolism;2024-06

4. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options;International Journal of Molecular Sciences;2024-05-22

5. PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis;Scientific Reports;2024-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3